Definitive Healthcare Corp. Q4 FY2025 earnings call

Management highlighted that significant progress was made in 2025 across strategic priorities, and in 2026, Q1 revenue is expected to be $54 - $56 million, full - year revenue $220 - $226 million. They are proactively managing costs, saw improvement in renewal rates in Q4 with some green shoots in demand environment, focused on churn improvement, added integrated customers in Q4, remediated claims data disruption, and are restarting product innovation engine with AI - related investments.

Not explicitly provided with detailed financial performance and revenue contribution percentage for specific product segments as the transcript focuses on overall business performance rather than distinct product segment breakdowns

Guidance for Q1: total revenue $54 - $56M, down 5% - 9% y - o - y; adjusted operating income $9.5 - $10.5M, adjusted EBITDA $12 - $13M, adjusted net income $4 - $5M. Full - year 2026: revenue $220 - $226M, down 6% - 9% y - o - y; adjusted operating income $41.5 - $46.5M, adjusted EBITDA $53 - $58M, adjusted net income $21 - $26M, with focus on maintaining margins while investing in growth areas.

Risks include top - line pressure, historical claims data disruption impact, and potential distraction of AI on budget allocation.

Q: Craig Hettenbach asked about demand environment across end markets and renewals from December and January, A: Response about churn improvement, cohort renewal performance, demand environment green shoots, and integrated customers; Q: Ryan McDowell asked about end markets in renewals and life sciences downsells, A: Response about gross dollar retention improvement in enterprise (life sciences - weighted), net dollar retention decline, product innovation, and business mix; Q: Brian Peterson asked about AI impact and NDR bottom, A: Response about healthcare - specific use cases, AI advantage with data, expectation of NDR improvement in 2026; Q: Jared Haas asked about go - to - market for upsells and product update communication, A: Response about five prongs in go - to - market, timing of product update impact on renewals; Q: George Hill asked about NDR recovery magnitude and claims data revenue impact, A: Response about claims data remediation, NDR modest improvement assumption; Q: Jeff Garoff asked about life sciences renewals and product innovation cadence, A: Response about life sciences stabilization, growth in diversified and provider, and product release cadence with Q2 focus